Pricing Log in Create free account

Evogene Ltd. (EVGN) vs Lexaria Bioscience Corp. (LEXX)

Evogene Ltd. and Lexaria Bioscience Corp. are both Biotechnology companies. Evogene Ltd. and Lexaria Bioscience Corp. are of similar size ($6.3M and $6.3M). Lexaria Bioscience Corp. grew revenue faster over the last twelve months: 9.08% against −54.7%. Lexaria Bioscience Corp. has the higher net margin (0.00% vs −547.6%) and the lower return on invested capital (−662.6% vs 0.00%). Across the 17 metrics below, Lexaria Bioscience Corp. leads on 9 and Evogene Ltd. on 8.

Valuation

Metric EVGN LEXX Biotechnology median
P/E n/m n/m 8.50
P/S 2.87 8.91 9.71
P/B 0.82 1.11 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.43 n/m 0.64
EV/Sales (2.77) 2.36 9.21
Earnings yield (233.33%) (174.57%) (33.15%)
Free cash flow yield (226.59%) (155.80%) (25.50%)

Profitability

Metric EVGN LEXX Biotechnology median
Gross margin (67.59%) 100.00% 65.16%
Operating margin (851.42%) 0.00% 0.00%
Net margin (547.62%) 0.00% 0.00%
Free cash flow margin (650.63%) 0.00% 0.00%
Return on equity (100.03%) (162.60%) (56.36%)
Return on assets (38.31%) (134.20%) (48.04%)
Return on invested capital 0.00% (662.56%) 0.00%

Growth

Metric EVGN LEXX Biotechnology median
Revenue growth (TTM) (54.71%) 9.08% 6.02%
EPS growth (last fiscal year) 62.63% (40.43%) 30.26%
Revenue growth, 5-year CAGR 29.94% 17.53% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EVGN LEXX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.57 10.60 4.72
Net debt to EBITDA 1.12 0.17 0.96

Dividend

Metric EVGN LEXX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric EVGN LEXX Biotechnology median
Market cap 6.32m 6.30m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack